Recent studies have shown blood phosphorylated tau (p-tau) forms to be reliable biomarkers in supporting a diagnosis of Alzheimer’s disease (AD) [1–5] and in screening for individuals with biomarker evidence of the disease in the absence of cognitive impairment [6–10]. This evidence concerns the gene MAPT and early-onset autosomal dominant Alzheimer disease.